Fresenius SE & Co. KGaA (FRE)
FRE · Health Care · 
Germany
Fresenius SE & Co. KGaA (FRE) is a German company in the Health Care sector. The stock has its largest weight in DBXD (DAX), at 1.08%. Anyone who holds an ETF containing Fresenius also has an indirect stake in the company.
Data and Charts: Fresenius
Key Data for Fresenius
Alysly Data Analysis: Fresenius
Fresenius Connections
The map shows how Fresenius connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- Germany Country · domicile
- Health Care Sector · sector
- Bayer Stock · similar ETF exposure
- Fresenius Medical Care Stock · similar ETF exposure
- Qiagen Stock · similar ETF exposure
- Siemens Healthineers Stock · similar ETF exposure
What ETF Is Fresenius In?
Fresenius has very high ETF coverage and is held by 31 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 99.0% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| DBXD / XDDA | DAX | 1.08% | €10.84 |
| EXS1 | DAX | 1.08% | €10.80 |
| ZPRE | MSCI EMU | 0.31% | €3.07 |
| XD5E | MSCI EMU | 0.30% | €3.03 |
| XEMU | MSCI EMU | 0.30% | €3.03 |
| SPFS | MSCI World Health Care | 0.25% | €2.45 |
| XDWH | MSCI World Health Care | 0.24% | €2.45 |
| SPYE | MSCI Europe | 0.17% | €1.70 |
| XMEU / XIEE | MSCI Europe | 0.16% | €1.61 |
| IMEA | MSCI Europe | 0.16% | €1.60 |
| XDEV | MSCI World Value | 0.15% | €1.52 |
| X600 / XESU | STOXX Europe 600 | 0.14% | €1.43 |
| XSX6 / XSX7 | STOXX Europe 600 | 0.14% | €1.43 |
| EXSA | STOXX Europe 600 | 0.14% | €1.40 |
| WVAL | MSCI World Value | 0.10% | €1.02 |
| EXUS / EXU1 | MSCI World ex USA | 0.09% | €0.90 |
| SPYI / SPSA | MSCI ACWI IMI | 0.06% | €0.57 |
| WIMI | MSCI World IMI | 0.03% | €0.32 |
| SWWD | MSCI World | 0.03% | €0.28 |
| SPPW | MSCI World | 0.03% | €0.28 |
| XDWD / XDWL | MSCI World | 0.02% | €0.24 |
| EUNL | MSCI World | 0.02% | €0.20 |
| IUSQ | MSCI ACWI | 0.02% | €0.20 |
| SPYY | MSCI ACWI | 0.02% | €0.20 |
The last column shows how much of €1,000 in one of these funds goes to Fresenius, based on each fund's latest holdings list.
Fresenius Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Fresenius had a weight of 0.05% on Sep 30, 2019 and 0.02% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.05% on Sep 30, 2019. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Fresenius overlaps with the rest of a portfolio.
Stocks With ETF Exposure Similar to Fresenius
| Stock | Shared ETFs | r |
|---|---|---|
| Fresenius | – | – |
| Fresenius Medical Care | 31 | – |
| Qiagen | 31 | – |
 Siemens Healthineers | 30 | – |
 Bayer | 31 | – |
| Continental | 29 | – |
 Volkswagen Non-Voting Pref | 29 | – |
| Biomerieux | 27 | – |
| Koninklijke Philips N.V. | 27 | – |
These stocks reach a portfolio through largely the same funds as Fresenius. “Shared ETFs” counts the funds that hold both.
Fundamental Analysis: Fresenius
Latest Patents Granted to Fresenius
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, Fresenius received 15 utility patents and 1 design patents. That is 0.005% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 3.3 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12751918 B2 | Ketamine formulation | A61K Human necessities | ||
| US 12742014 B2 | Liquid pharmaceutical composition comprising an anti-il-6 receptor antibody | C07K Chemistry; metallurgy | ||
| US 12734309 B2 | Syringe, syringe body and method for the production thereof | A61M Human necessities | ||
| US 12691642 B2 | Pulse welding method and welding tool for pulse welding for a medical pack formed as a bag | B29C Performing operations; transporting | ||
| US 12678373 B2 | Valve unit for a system for producing a medical preparation | A61J Human necessities |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: Fresenius Kabi Deutschland GmbH and Fresenius Kabi USA, LLC. Titles as published by the office; median time based on 11 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
